Why does rosacea affect women more, and get worse at 40?
Rosacea is vascular and immune dysregulation. Estrogen protects by supporting skin barrier function, modulating inflammation, and helping regulate blood vessel tone. When estrogen fluctuates and declines in perimenopause, that protective buffer diminishes. A lot of rosacea advice focuses on triggers (spicy food, alcohol, temperature) and misses the hormonal foundation entirely.
Estrogen decline amplifies the release of cathelicidins: antimicrobial peptides that, when dysregulated, drive rosacea's inflammatory cascade. This explains why many women had mild rosacea at 30 but suddenly see it worsen significantly at 40, coinciding with perimenopausal shifts. Most women don't connect their age to rosacea worsening. They assume it's new triggers when it's actually hormonal.
Hot flashes add a second hit: they trigger the same vascular flushing response as external rosacea triggers. Your skin is already hyperreactive, and internal temperature spikes fuel further inflammation. This changes what treatments might actually address the root cause.
A 2019 Cochrane Review by van Zuuren et al. evaluated 152 randomised controlled trials and found that topical azelaic acid 15–20% and topical metronidazole 0.75–1% have the strongest evidence for reducing inflammatory papules and pustules in papulopustular rosacea. The review also confirmed that brimonidine 0.33% gel has good evidence for managing persistent erythema (redness).
What are the four subtypes, and which one do you have?
Subtype 1 (Erythematotelangiectatic rosacea or ETR) is most common in women and presents as persistent facial redness, flushing, and visible capillaries. Your face feels reactive to temperature, wind, and products. This is the subtype most responsive to hormonal factors.
Subtype 2 (Papulopustular rosacea or PPR) adds acne-like bumps and pustules to redness. It's often misdiagnosed as adult acne, but the absence of blackheads distinguishes it. A lot of women get treated for acne when they actually have rosacea. This is where most go wrong: the treatments are completely different. Subtype 3 (Phymatous rosacea) involves skin thickening, especially on the nose (and is far more common in men). Subtype 4 (Ocular rosacea) affects the eyes and eyelids with dryness, irritation, and recurrent styes, often appearing before facial symptoms.
Keep a two-week trigger diary noting flush episodes alongside food, temperature, stress, skincare products, and hormonal timing. Patterns typically emerge within 10–14 days and give your dermatologist far more actionable information than a single appointment can.
What the evidence says about treatment
For ETR and PPR, first-line evidence supports topical azelaic acid 15-20% (prescription), topical metronidazole 0.75-1%, and topical ivermectin 1%. Azelaic acid also supports skin barrier function (relevant if your rosacea is triggered by reactive skin).
For persistent redness, topical brimonidine works by constricting blood vessels. It's effective but short-acting (8-12 hours) and can cause rebound redness if used daily without breaks. Oral low-dose doxycycline 40mg (the anti-inflammatory dose, not antimicrobial dose) has good evidence for PPR and bridges while topicals work.
Topical azelaic acid or metronidazole
Reduces papules, pustules, and redness. Studies used 15–20% azelaic acid or 0.75–1% metronidazole applied once or twice daily. Consult your doctor for the appropriate regimen.
Topical brimonidine 0.33% gel
Research indicates effective short-term vasoconstriction for erythematotelangiectatic rosacea. Use as advised by your prescriber; discuss any treatment plan with your doctor.
IPL (Intense Pulsed Light) or vascular laser
Studies show significant reduction in visible telangiectasia and persistent erythema with multiple IPL or pulsed-dye laser sessions; results are sustained but not permanent. Requires specialist referral.
What to tell your doctor
- "I think my rosacea is getting worse around perimenopause: could hormonal changes be involved?" Opens the conversation about the estrogen link; some doctors may not connect these without prompting.
- "Can you confirm my rosacea subtype before we discuss treatment?" Subtype drives the entire treatment decision: misidentification leads to ineffective or counterproductive treatment.
- "Which of these treatments is appropriate for daily use vs as-needed use?" Brimonidine and some laser treatments have specific usage patterns to avoid rebound.
When to see a dermatologist
See a dermatologist if your rosacea involves the eyes (gritty, dry, recurring styes), if skin thickening develops around the nose or chin, if over-the-counter treatments have not helped within 8 weeks, or if your symptoms are significantly impacting your quality of life. Perimenopause-triggered worsening is also worth discussing with your doctor to assess whether hormonal factors can be addressed directly.
References
- Cribier B. Rosacea under the microscope: characteristic histological findings. Journal of the European Academy of Dermatology and Venereology. 2013;27(11):1336–1343. doi:10.1111/jdv.12014
- Rainer BM, et al. Characterization and analysis of the skin microbiota in rosacea: a case-control study. Experimental Dermatology. 2017;26(9):826–828. doi:10.1111/exd.13163
- van Zuuren EJ, et al. Interventions for rosacea. Cochrane Database of Systematic Reviews. 2019;(9):CD003262. doi:10.1002/14651858.CD003262.pub6
- Two AM, Wu W, Gallo RL, Hata TR. Rosacea: part I. Introduction, categorization, histology, pathogenesis, and risk factors. Journal of the American Academy of Dermatology. 2015;72(5):749–758. PubMed